BIOMEA FUSION INC (BMEA) Stock Price, Forecast & Analysis
NASDAQ:BMEA • US09077A1060
BMEA Key Statistics, Chart & Performance
The current stock price of BMEA is 1.33 USD. In the past month the price increased by 20.91%. In the past year, price decreased by -50.92%.
BMEA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BMEA. When comparing the yearly performance of all stocks, BMEA is a bad performer in the overall market: 84.85% of all stocks are doing better.
BMEA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMEA. While BMEA seems to be doing ok healthwise, there are quite some concerns on its profitability.
BMEA Financial Highlights
Over the last trailing twelve months BMEA reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 40.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.43% | ||
| ROE | -612.79% | ||
| Debt/Equity | 0 |
BMEA Forecast & Estimates
13 analysts have analysed BMEA and the average price target is 7.14 USD. This implies a price increase of 436.84% is expected in the next year compared to the current price of 1.33.
BMEA Ownership
BMEA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.1 | 414.026B | ||
| AMGN | AMGEN INC | 16.73 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.57 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.1 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.69 | 22.521B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BMEA
Company Profile
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 42 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Company Info
BIOMEA FUSION INC
1599 Industrial Road
San Carlos CALIFORNIA US
Employees: 42
Phone: 13026587581
BIOMEA FUSION INC / BMEA FAQ
Can you describe the business of BIOMEA FUSION INC?
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 42 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Can you provide the latest stock price for BIOMEA FUSION INC?
The current stock price of BMEA is 1.33 USD. The price decreased by -2.92% in the last trading session.
Does BIOMEA FUSION INC pay dividends?
BMEA does not pay a dividend.
How is the ChartMill rating for BIOMEA FUSION INC?
BMEA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for BIOMEA FUSION INC?
BIOMEA FUSION INC (BMEA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for BIOMEA FUSION INC?
BIOMEA FUSION INC (BMEA) currently has 42 employees.